Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 revenue/EPS ahead of Street as U.S. Farapulse roughly doubled quarter-over-quarter, which significantly exceeded Street expectations. Wells further notes that Boston Scientific raised 2024 revenue/EPS guidance by the beat and provided early 2025 color.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $98 from $92 at Citi
- Boston Scientific (NYSE:BSX) Q3 Earnings Show Significant Sales Growth
- Boston Scientific weakness a buying opportunity, says Stifel
- Boston Scientific price target raised to $97 from $93 at BTIG
- Unusually active option classes on open October 23rd